Hoxa9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of Hoxa9-dependent leukemia by Brumatti, G. et al.
PUBLISHED VERSION  
http://hdl.handle.net/2440/82428  
 
Gabriela Brumatti, Marika Salmanidis, Chung H Kok, Rebecca A Bilardi, Jarrod J Sandow, Natasha 
Silke, Kylie Mason, Jolanda Visser, Anissa M Jabbour, Stefan P Glaser, Toru Okamoto, Philippe 
Bouillet, Richard J D'Andrea, and Paul G Ekert 
Hoxa9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of 
Hoxa9-dependent leukemia 
Oncotarget, 2013; 4(11):1933-1947 
© 2013 Brumatti et al. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original author and source are credited 






























www.impactjournals.com/oncotarget/ Oncotarget, November, Vol.4, No 11
HoxA9 regulated Bcl-2 expression mediates survival of myeloid 
progenitors and the severity of HoxA9-dependent leukemia
Gabriela Brumatti1,2, Marika Salmanidis1,2,4*, Chung H Kok6, Rebecca A Bilardi1,2, 
Jarrod J Sandow1,2, Natasha Silke1,2, Kylie Mason1,5, Jolanda Visser1,7, Anissa 
M Jabbour1,2, Stefan P Glaser1,2, Toru Okamoto8, Philippe Bouillet1,2, Richard J 
D’Andrea6, and Paul G Ekert1,2,3,4
1 Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Australia
2 Department of Medical Biology, University of Melbourne, Parkville, Australia
3 Murdoch Children’s Research Institute and Children’s Cancer Centre, Royal Children’s Hospital, Parkville,  Australia
4 Department of Pediatrics, University of Melbourne, Parkville, Australia
5 Department of Medicine, University of Melbourne, Parkville, Australia
6 Department of Hematology and Centre for Cancer Biology, SA Pathology, Adelaide; Department of Hematology and 
Oncology, the Queen Elizabeth Hospital, Woodville, Australia; The Discipline of Medicine, University of Adelaide.
7 University Medical Center Groningen, Hanzeplein 1, Groningen, Netherland
8 Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, 
Osaka, Japan
* Present address: Centre for Cancer Biology, SA Pathology, Adelaide, Australia.
Correspondence to: Paul Ekert, email: ekert@wehi.edu.au
Keywords: HoxA9, Bcl-2, Leukemia, apoptosis
Received:  August 20, 2013 Accepted: September 13, 2013 Published: September 15, 2013
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT:
Deregulated expression of Hox genes such as HoxA9 is associated with 
development of myeloproliferative disorders and leukemia and indicates a poor 
prognosis. To investigate the molecular mechanisms by which HoxA9 promotes 
immortalization of hematopoietic cells, we generated growth factor dependent 
myeloid cells in which HoxA9 expression is regulated by administration of 4-hydroxy-
tamoxifen. Maintenance of HoxA9 overexpression is required for continued cell survival 
and proliferation, even in the presence of growth factors. We show for the first time 
that maintenance of Bcl-2 expression is critical for HoxA9-dependent immortalization 
and influences the latency of HoxA9-dependent leukemia. Hematopoietic cells lacking 
Bcl-2 were not immortalized by HoxA9 in vitro. Furthermore, deletion of Bcl-2 delayed 
the onset and reduced the severity of HoxA9/Meis1 and MLL-AF9 leukemias. This is 
the first description of a molecular link between HoxA9 and the regulation of Bcl-2 
family members in acute myeloid leukemia. 
INTRODUCTION
The Hox genes are a family of highly conserved 
transcriptional regulators with critical roles in normal 
development and hematopoiesis [1-3]. Elevated expression 
of HoxA9 is strongly and causally associated with the 
development of myeloid leukemia and correlates with 
a poor prognosis [4]. HoxA9 overexpression frequently 
occurs in association with rearrangements of the Mixed 
Lineage Leukemia locus at 11q23 (MLL) [5,6], but is 
also associated with trisomy 8 AML [7] and the t(7;11)
(p15;p15) translocation which fuses NUP98 to HoxA9 [8]. 
Transformation of myeloid progenitor cells by transgenic 
expression of MLL rearrangements is dependent on the 
expression of HoxA group genes, in particular HoxA9 
[9,10]. 
HoxA9 overexpression maintains the self-renewal 
capacity of leukemic stem cells and blocks differentiation 
[11,12], inducing a gene-expression signature associated 
with hematopoietic self-renewal potential [6]. HoxA9 
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regulates transcription in complex with homeodomain-
containing proteins of the Pre-B cell/CEH-20 family (PBC 
proteins, Pbx proteins in vertebrates) and the Meis family, 
particularly Meis1 [13-15]. Hox-Pbx binding requires a 
hexapeptide motif containing a critical tryptophan residue 
in the Hox proteins [16]. Mutation of the hexapeptide 
domain of HoxA9 abolishes its activity to immortalize 
myeloid cells [11]. 
Chromatin-immunoprecipitation and sequencing 
(ChIP-seq), combined with expression microarrays, have 
mapped potential HoxA9-regulated genes [17,18]. These 
studies suggest HoxA9 functions as a transcriptional 
enhancer, which together with Meis 1 and lineage-
restricted transcription factors, activate leukemia-
associated proto-oncogenes that include Myb and Flt3 
[17]. 
Several lines of evidence indicate that HoxA9 
regulates pathways that control cell survival. For example, 
increased apoptosis is observed in the fetal thymus 
of HoxA9-/- mice [3] and silenced HoxA9 expression 
induces apoptosis in human AML lines bearing MLL 
rearrangements [18], suggesting that one function of 
HoxA9 is to repress apoptosis pathways. 
To investigate how HoxA9 regulates cell viability, 
we used a lentiviral expression system to express 
HoxA9 in myeloid progenitor cells under the control of 
a 4-hydroxy-tamoxifen (4-OHT) inducible promoter. 
Downregulation of HoxA9 expression induced apoptosis 
in the majority of cells and was correlated with the loss of 
Bcl-2 expression. Moreover, deletion of Bcl-2 expression 
in HoxA9 factor-dependent cells induced apoptosis. In 
HoxA9/Meis1 and MLL-AF9-dependent AML, deletion 
of Bcl-2 dramatically altered clinical features, resulting in 
longer survival, diminished peripheral white cell counts 
and more destructive splenic disease. Together our data 
show that HoxA9 regulated Bcl-2 expression is important 
for the survival of myeloid progenitors and contributes to 
the oncogenic effects of HoxA9 overexpression.
RESULTS
HoxA9 expression is required for survival and 
clonogenic proliferation of IL-3 and GM-CSF 
dependent myeloid progenitor cells
HoxA9 overexpression immortalizes myeloid 
progenitor cells dependent on cytokines such as IL-3 or 
GM-CSF. To explore the consequences of varying HoxA9 
expression, we infected c-kit+/lin- myeloid progenitor cells 
with lentivirus encoding a Flag-tagged HoxA9 under the 
control of a 4-OHT-inducible promoter to generate HoxA9 
Factor Dependent Myeloid (FDM) cells. For simplicity, 
we refer to the 4-OHT-induced expression of HoxA9 
as HoxA9on, and the absence of 4-OHT as HoxA9off. 
Consistent with previous results [11], overexpression of 
Flag-HoxA9, but not Flag-HoxA9 lacking the hexapeptide 
domain, efficiently immortalized myeloid progenitor 
cells (Figure 1A), even with 10 fold higher cytokine 
concentrations (Supplementary Figure S1A). We tested 
various cytokine combinations to determine which ones 
maintain HoxA9 FDM cell viability (Figure 1B). Only 
IL-3 or GM-CSF or the combination of those kept cells 
alive. In contrast, Stem Cell Factor (SCF) was insufficient 
to maintain cell survival. Cytokine removal resulted in 
rapid apoptosis, indicating that these cells were strictly 
cytokine-dependent (Supplementary Figure S1B). We 
then compared the expression of surface lineage markers 
in HoxA9on and HoxA9off cells cultured in GM-CSF. In 
the HoxA9off state, a proportion of cells differentiated, as 
described by others [11], indicated by increased F4/80 
(macrophage/monocyte marker) and Gr-1 (granulocyte 
marker) expression (Figure 1C).
The majority of HoxA9off cells were refractory to 
the proliferative signals transduced by IL-3 or GM-CSF, 
resulting in declined cell viability after 4 days in HoxA9off 
conditions (Figure 1D, Supplementary Figure S1A-C). 
This effect was more pronounced in cells cultured in IL-3 
compared to GM-CSF. Loss of viability was preceded 
by a decline in the proportion of cells in S-phase (Figure 
1E). Clonogenic assays showed that HoxA9off FDM 
cells failed to form colonies, even in 10-fold higher 
concentrations of IL-3 or GM-CSF (Supplementary Figure 
S1C). Importantly, the kinetics of cell death in response 
to HoxA9off was slower than that induced by cytokine 
deprivation (compare Figure 1D to Supplementary Figure 
S1B). Together these data demonstrate that the loss of 
HoxA9 expression induced cells to stop dividing and 
undergo apoptosis. 
We next determined whether loss of HoxA9 
expression also prevented colony formation in cells that 
endogenously produce cytokines. HoxA9 FDM cells 
infected with a retrovirus encoding IL-3 or a control virus 
were cultured in soft agar in the presence or absence of 
IL-3 and HoxA9 (Figure 1F). Endogenously produced, or 
exogenously provided IL-3 promoted colony formation 
in HoxA9on but not HoxA9off cells, demonstrating 
that autonomous IL-3 signaling is sufficient to permit 
proliferation and viability of hematopoietic progenitor 
cells only provided HoxA9 expression is maintained.
It has been shown in HoxA9-immortalized 
hematopoietic cells that HoxA9 downregulation results 
in decreased transcription of IL-3 receptor α chain (IL-
3α or CD123), ß common chain (βc or CD131), CD135 
(Flt3) and reduced CD34 expression [17]. We determined 
the levels of these markers in multiple independent lines 
in HoxA9on and HoxA9off (Figure 1G and Supplementary 
Figure S1D). The expression of IL-3Rα, βc and CD34 
protein always decreased in HoxA9off cells, while CD135 
levels remained virtually undetectable. These data indicate 
that once HoxA9 is turned off, the expression of the IL-3/
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Figure 1: HoxA9 overexpression is required for proliferation and survival of growth factor dependent myeloid cells. 
(A) Hematopoietic progenitor cells were transduced with GFP, Flag-HoxA9 or Flag- hexapeptide mutant HoxA9 and cultured in soft agar 
in the presence of the IL-3 (0.5ng/ml) and GM-CSF (2.5ng/ml). After 14 days, number of colonies was counted and the results expressed 
as colonies per 1000 cells plated.  Results are means ±SEM of 3 independent experiments using 3 independent pools of cells. Inset shows 
lysates from c-kit+/Lin- myeloid precursors immortalized with inducible Flag-tagged HoxA9, cultured in the presence (Day 0) or absence 
of 4-OHT probed with an anti-HoxA9 and anti-Actin antibodies as a loading control. (B) Viability of HoxA9 FDM cells cultured in the 
presence of the indicated cytokines for 48 hours was determined by flow cytometric measurement of AnnexinV staining and PI exclusion. 
Results show the means ± SEM of 4 independent experiments.  (C) HoxA9 FDM cells maintained in GM-CSF were cultured in the presence 
or absence of 4-OHT for 4 days. Cells were stained with antibodies to the indicated surface lineage markers and expression assessed by 
flow cytometry. Unstained cells represented by the dashed line act as a control. Cells expressing HoxA9 (HoxA9on) are represented by the 
solid line and cells in which HoxA9 has been downregulated (HoxA9off) are indicated by the filled histogram. Representative histograms 
are shown. (D) The viability of HoxA9 FDM cells was determined using flow cytometric determination of AnnexinV-FITC staining and PI 
exclusion, at 0, 4 and 8 days following removal of 4-OHT from cultures to downregulate HoxA9 expression. Results are means ±SEM of 
4 clones repeated in 2 independent experiments. (E) HoxA9 FDM cells were cultured in the absence of 4-OHT for 8 days. At the indicated 
time points, cells were stained using a hypotonic PI buffer solution and the percentage of cells in S phase determined by flow cytometry. 
The results are means ±SEM of 4 clones repeated 2 independent experiments. (F) HoxA9 FDM cells were infected with retrovirus encoding 
IL-3 or empty control virus. Infected cells were plated in soft agar in the presence or absence of 4-OHT and presence or absence of 
exogenous IL-3. The number of colonies per 1000 cells plated was determined after 10 days in culture. Results show means ±SEM of 3 
independent experiments using 2 independent pools of HoxA9 infected cells. Representative example of colony formation in the assays 
is shown below. (G) HoxA9 FDM cells cultured in the presence of IL-3 and GM-CSF were stained with antibodies to detect the indicated 
components of the IL-3 receptor 3 and 5 days after 4-OHT deprivation. Expression was analyzed by flow cytometry. Data are means ±SEM 
of 3 independent experiments from 4 independent pools of HoxA9 infected cells.
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GM-CSF receptors declines, which may contribute to the 
unresponsiveness to these cytokines.
Altering HoxA9 expression changes Bcl-2 
expression levels
Apoptosis mediated by IL-3 withdrawal is regulated 
by members of the Bcl-2 family of proteins [18]. Since 
loss of HoxA9 made cells refractory to survival signals 
transduced by IL-3, we looked for changes in anti-
apoptotic Bcl-2 family member expression in response 
to turning off HoxA9 expression (Figure 2A). We 
consistently observed reduced Bcl-2 protein expression in 
cell lines in the HoxA9off state, whereas Mcl-1 and Bcl-
xL expression remained unchanged and A1 expression 
was increased. Consistent with the changes in protein 
expression, Bcl-2 mRNA decreased in HoxA9off cells 
(Figure 2B). When HoxA9 expression was turned back 
on, Bcl-2 returned to levels similar to those prior to 
removal of 4-OHT (Figure 2C), emphasizing a direct 
correlation between induced HoxA9 expression and Bcl-2 
levels. We looked for conserved HoxA9/Meis1 binding in 
Bcl-2 family members using previously published Chip-
sequence data (GSE38339 and GSE33518). Only Bcl-2 
showed conserved HoxA9 binding consistent with other 
validate HoxA9 targets (Supplemental Figure 4B-D) 
To determine if the diminished Bcl-2 expression 
was due to cell loss via apoptosis, we immortalized 
hematopoietic progenitor cells from mice lacking the key 
apoptosis regulators Bax and Bak. These cells are resistant 
to apoptosis induced by cytokine deprivation [19]. Bax-/-
;Bak-/- HoxA9off FDM cells remained viable, however Bcl-
2 expression still decreased (Figure 3A and B), showing 
that varying HoxA9 expression resulted in concomitant 
changes in Bcl-2 expression. 
We speculated that changes in Bcl-2 expression 
following HoxA9 downregulation would alter the 
sensitivity of HoxA9 FDM cells to chemotherapeutic 
agents. However despite the changes in Bcl-2 family 
member expression in HoxA9on or HoxA9off conditions, the 
susceptibility to apoptosis induced by chemotherapeutic 
drugs was not altered. This included the BH3 mimetic 
drug ABT-737 (Supplementary Figure S2A and B). Mcl-
1 expression was not affected by HoxA9 expression, 
probably accounting for the unchanged sensitivity to ABT-
737. 
Figure 2: Downregulated HoxA9 expression results in loss of Bcl-2 expression. (A) HoxA9 FDM cells were cultured in media 
containing GM-CSF and IL-3 in the presence (Day 0) or absence of 4-OHT (HoxA9off) over 8 days. At the indicated times, lysates were 
harvested and Western blots probed with antibodies against HoxA9, Bcl-2, Mcl-1 and Bcl-xL, Actin was used as a loading control. (B) Bcl-
2 mRNA levels were determined by qRT-PCR using total RNA derived from HoxA9 FDM cells cultured in the presence of cytokines and 
absence of 4-OHT for 6 days. mRNA levels of Bcl-2 were normalized to Sdh2a and Polr2a. Results show mean ± SE from 4 independent 
pools or clones each of IL-3- and GM-CSF-dependent FDM cells repeated in 2 independent experiments. (C) HoxA9 FDM cells, maintained 
in IL-3 and GM-CSF, were cultured without 4-OHT (HoxA9off) followed by 4-OHT re-addition (HoxA9on). Lysates were generated at the 
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Bcl-2 is required for HoxA9-dependent 
immortalization in vitro
We next addressed the role of Bcl-2 in HoxA9-
dependent immortalization of myeloid progenitor cells by 
attempting to generate HoxA9 FDM cells from wild-type 
(Bcl-2+/+), Bcl-2+/- and Bcl-2-/- mice. After transduction 
with HoxA9 lentivirus and selection for infection, equal 
cell numbers of Bcl-2+/+, Bcl-2+/- and Bcl-2-/- cells were 
seeded in liquid culture containing cytokines and cell 
numbers were assessed over 9 days. The numbers of 
wild-type and Bcl-2+/- cells increased steadily, consistent 
with HoxA9-dependent immortalization (Figure 4A). The 
plateau in the rate of proliferation by day 9 was a result of 
cells exiting log phase growth due to high cell numbers 
in the culture dishes. The numbers of Bcl-2-/- HoxA9 
infected cells did not increase in the same time period 
(Figure 4A). To exclude the possibility that progenitor 
cells from Bcl-2-/- mice generally fail to be immortalized 
by Hox genes, we compared the ability of HoxA9 and 
HoxB8 to generate FDM cells. Equal cell numbers of 
wild type and Bcl-2-/- cells were infected with lentivirus 
of matched MOI encoding HoxA9 or HoxB8 and cell 
numbers were assessed over a 9 days period (Figure 4B). 
HoxB8 and HoxA9 infection induced rapid proliferation 
of wild type cells but only HoxB8 induced proliferation 
of Bcl-2-/- cells and permitted the establishment of cell 
lines. HoxB8 immortalized Bcl-2-/- cells expressed similar 
surface lineage markers as wild type cells (Supplementary 
Figure S3A). Moreover, turning off HoxB8 expression in 
wild type cells did not induce changes in Bcl-2 expression 
as observed in HoxA9 cells (Figure 4C). These data 
indicate that in contrast to HoxB8, HoxA9 requires Bcl-2 
to immortalize cytokine dependent myeloid cells.
Eventually, cells did grow out from liquid cultures 
of HoxA9-infected Bcl-2-/- cells or the rare colony 
formed in soft-agar. These cells differed from HoxA9-
immortalized wild type cells. A much higher proportion of 
Bcl-2-/- cells expressed the natural killer cell marker NK1.1 
(Supplementary Figure S3B). Importantly, the viability 
of these surviving Bcl-2-/- cells was less dependent on 
HoxA9 expression (Figure 4D). These results confirm that 
the rapid immortalization of progenitor cells by HoxA9 
required the presence of at least one copy of Bcl-2.
The t(7:11)(p15:p15) translocation, which fuses the 
nucleoporin Nup98 to the homeodomain of HoxA9, has 
been identified in AML patients. To investigate whether 
deletion of Bcl-2 also impaired immortalization of 
myeloid cells by Nup98-HoxA9, hematopoietic progenitor 
cells were infected with lentivirus encoding Nup98-
HoxA9 under the control of a tetracycline-inducible 
promoter. Compared to HoxA9 tetracycline-inducible 
FDMs, expression of both HoxA9 and Nup98-HoxA9 was 
repressed by the removal of Doxycycline from the media 
(Figure 5A) however, only HoxA9 cells presented changes 
on Bcl-2 expression. We then infected hematopoietic 
progenitor cells from Bcl-2+/+ and Bcl-2-/- mice with 
HoxA9, Nup98-HoxA9 or HoxB8 and maintained cells 
in high concentration of cytokines. Cells were replated at 
equal numbers 7 days after infection (Day 0) and counted 
over 56 days. Nup98-HoxA9 immortalized wild-type and 
Bcl-2-/- cells with similar efficiency (bottom panel Figure 
5B). HoxA9-infected Bcl-2-/- cells proliferated at the 
same rate as wild-type cells for up to 28 days, after which 
proliferation ceased. This was in contrast of the previous 
results and shows that in extended assays, some initial 
proliferation of Bcl-2-/- cells will occur (top panel Figure 
5B compare to Figure 4A and B). One critical distinction 
between the short-term (Figure 4A and B) and the long-
term (Figure 5B) assays is that cells in Figure 4 have been 
selected in puromycin and maintained in culture for up 
Figure 3: Decline in Bcl-2 expression in HoxA9-dependent myeloid cells is independent of apoptotic cell death. (A) The 
viability of wild type and Bax;Bak-/- HoxA9 FDM cells was determined by flow cytometry  analysis of AnnexinV-FITC staining and PI 
exclusion, at 0, 4, 8 and 12 days following removal of 4-OHT. Results are means ±SEM of 2 pools and 2 clones repeated in 3 independent 
experiments. (B) Bax;Bak-/- HoxA9 immortalized cells were cultured in the presence (Day 0) or absence of 4-OHT over 6 days. At the 
indicated times, lysates were harvested and Western blots probed with antibodies against HoxA9, Bcl-2, Mcl-1 and Bcl-xL. Actin was used 
as a loading control.


































to 30 days before the assays were performed, therefore 
bypassing the initial proliferation phase, which explains 
the different patterns of proliferation observed in these 
experiments. The period of initial proliferation, in the 
absence of selection, of Bcl-2-/- cells in the first 28 days 
(Figure 5B) corresponds to the time taken for puromycin 
selection of cells shown in Figure 4A and B. As before, 
HoxB8 infection immortalized Bcl-2-/- progenitor cells 
(middle panel Figure 5B). At 21 and 42 days, cells were 
removed from these cultures and plated at equal density 
in soft agar and the number of colonies was counted. No 
significant difference was observed in the colony numbers 
of Bcl-2+/+ and Bcl-2-/- progenitor cells immortalized with 
HoxB8 or Nup98-HoxA9 (Figure 5C and Supplementary 
Figure S3C). However, decreased colony formation in 
HoxA9-infected Bcl-2-/- cells was observed. These data 
show that the requirement for Bcl-2 in the immortalization 
of progenitor cells is waived when cells are infected 
with Nup98-HoxA9. This was further supported by the 
findings that in the presence or absence of Nup98-HoxA9 
expression, Bcl-2 expression was unchanged (Figure 5A).
Having shown that Bcl-2 was required for HoxA9-
dependent immortalization, we next asked whether this 
requirement persisted after cells were immortalized. We 
harvested bone marrow from mice homozygous for Bcl-
xL, Mcl-1 or Bcl-2 alleles flanked by LoxP sites [20- 22] 
that had been crossed with syngeneic mice expressing 
cre-recombinase fused to a modified estrogen receptor 
tag (Rosa26:Cre-ERT2) expressed from the Rosa 26 
locus [23].  Bone marrow stem cells from these animals 
were immortalized by infection with virus encoding 
constitutively expressed HoxA9 or Nup98-HoxA9, in 
the continuous presence of IL-3 and GM-CSF. Once 
continuously proliferating, 4-OHT was added to cultures 
to induce deletion of Bcl-xL, Mcl-1 or Bcl-2 and viability 
was determined (Figure 5D). Western blot demonstrated 
efficient deletion of the LoxP-flanked alleles (Figure 5E). 
Deletion of Mcl-1 reduced viability in both HoxA9 and 
Nup98-HoxA9 infected cells, consistent with the published 
role for Mcl-1 in the survival of hematopoietic cells [24] 
(Figure 5D and Supplementary Figure S3D). Deletion of 
Bcl-2 reduced the viability of HoxA9-immortalized cells, 
but not of Nup98-HoxA9 cells (Figure 5D). Deletion of 
Bcl-xL had no significant impact on cell viability of either 
sets of cells. Together, these data provide further evidence 
that Bcl-2 expression is specifically required to maintain 
cytokine-dependent viability of HoxA9-immortalized 
cells.
Figure 4: Bcl-2 is required for HoxA9-dependent immortalization of myeloid cells. (A-B) Hematopoietic progenitor cells 
from Bcl-2+/+, Bcl-2+/- and Bcl-2-/- littermates were infected with HoxA9 or HoxB8 and selected for 10 days in media containing IL-3 (0.5ng/
ml) (HoxB8) or IL-3 and GM-CSF (2.5ng/ml) (HoxA9) and 0.5ug/ml puromycin. Cells were then replated in liquid culture at several 
known dilutions (day 0) and cell number determined at the indicated days and expressed as a value relative to the number of cells plated 
on day 0. HoxA9-immortalized cells data are means ±SEM from 5 independently infected pools of Bcl-2+/+, 6 independent pools of Bcl-2+/- 
and 7 independent pools of Bcl-2-/- performed in 3 independent experiments. HoxB8-immortalized cells results are means ±SEM from 3 
independent experiments of 3 independent pools from each genotype. (C) Hematopoietic stem cells from wild type mice were immortalized 
with lentivirus encoding HoxB8 under the control of a tetracycline-inducible promoter. Cells were cultured in the presence or absence of 
1.5μg/ml doxycycline and lysates probed with antibodies to detect Bcl-2, HoxB8 and Actin as a loading control. Two independent pools (P1 
and P2) are shown. (D) Hematopoietic cells derived from Bcl-2+/+, Bcl-2-/+ and Bcl-2-/- mice, infected with HoxA9 lentivirus, were cultured 
in the presence (HoxA9on) or absence (HoxA9off) of 4-OHT. Viability was then determined by flow cytometry analysis of AnnexinV-FITC 
staining and PI exclusion.  Results are means ±SEM of 3 independent clones from each genotype repeated in 2 independent experiments. 
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11q23 rearrangements are associated with 
increased Bcl-2 expression
In human AML, elevated HoxA9 expression is 
strongly associated with rearrangements of the Mixed 
Lineage Leukemia locus (11q23 or MLL) [25-28]. To 
explore a possible association between HoxA9 and Bcl-2 
expression in human AML cell lines and patient samples, 
we probed lysates from a range of leukemic cell lines for 
HoxA9 and Bcl-2 expression (Figure 6A). In five of six 
Figure 5: HoxA9-dependent hematopoietic cells but not Nup98-HoxA9 or HoxB8, requires Bcl-2 expression for 
immortalization and survival. (A) Hematopoietic progenitor cells were immortalized by infection with lentivirus encoding HoxA9 or 
Nup98-HoxA9 under the control of a tetracycline-repressible promoter. Cells were cultured in the absence (Day 0) or presence of 1.5μg/ml 
doxycycline for the indicated time course. Lysates were harvested and probed with antibodies against HoxA9, Bcl-2 and actin was used as a 
loading control. (B) Hematopoietic progenitor cells derived from Bcl-2+/+ and Bcl-2-/- were infected with HoxA9, HoxB8 or Nup98-HoxA9 
and cultured in the presence of IL-3 (5ng/ml) alone (HoxB8) or IL-3 and GM-CSF (10ng/ml) (HoxA9 and Nup98-HoxA9). Seven days 
after infection, cells were replated at 2.5x 105cells/ml or 5x 105cells/ml and counted at the indicated time points over a 56 day time course. 
Cells were passage at known dilutions every 3-4 days. Results are means ±SEM from 3 independent experiments of 6 independent pools 
from each genotype. (C) At day 42 of the experiments described in (B), cells were plated in 0.3% soft agar in the presence of cytokines 
and 4-OHT. Colonies were counted after 14 days. Results are means ±SEM of 3 independent experiments of 6 independent pools from 
each genotype. (D) Hematopoietic progenitor cells from mice with homozygous LoxP-flanked Bcl-2, Mcl-1 or Bcl-xL alleles crossed with 
Rosa:Cre-ER were infected with HoxA9 (filled bars) or Nup98-HoxA9 (unfilled bars) and cultured in IL-3 and GM-CSF. Cells were then 
treated with 65nM of 4-OHT to induce deletion of the LoxP allele and viability measures using flow cytometry measurement of Annexin 
V-FITC staining and PI exclusion 72 hours later. Results show means ±SEM of 5 independent experiments from HoxA9 FDM cells and 
4 independent experiments from Nup98-HoxA9 FDMs. (*) P <0.05 and (***) P <0.0005. (E) Western blot of representative pools of 
cells from (D) probed with antibodies against Bcl-2, Bcl-xL and Mcl-1. Note the conditional allele of Mcl-1 runs at a higher MW than the 
endogenous allele.
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HoxA9 expressing cell lines, detectable HoxA9 expression 
was accompanied by higher Bcl-2 expression. Although 
all these lines have complex cytogenetic profiles, the two 
lines that also harbour 11q23 rearrangements, MV4;11 and 
THP-1, both had elevated HoxA9 and Bcl-2 expression. 
MV4;11 also carries a FLT3-ITD mutation. HL-60 cells 
also had elevated Bcl-2 expression, which may also be 
driven by c-Myc amplification. We tested the sensitivity 
of selected lines with elevated Bcl-2 expression to BH3-
mimetic ABT-199, and used U937 lymphoma cells with 
reduced Bcl-2 expression as a comparison (Figure 6B). 
Cells were treated with 1µM ABT-199 and viability was 
determined after 48 hours (Figure 6B). MV4-11, THP-1, 
and HL-60 cells underwent apoptosis in response to the 
Bcl-2 inhibitor. As previously observed in HoxA9 FDMs 
(Figure 5D), this result suggests that Bcl-2 a required 
for the survival of HoxA9High cells and its inhibition has 
significant impact on cell viability.
Recently, Valk et al studied the gene expression 
profile in 285 human AML patient samples [29], which 
were subsequently categorized into 16 subgroups based 
on expression array profiles (GSE1159) (Figure 6C and 
Supplemental Table S1). We therefore checked for the 
association between HoxA9 and Bcl-2 expression in these 
publically available expression arrays.  Of the subgroups 
suggested by Valk et al, those with 11q23 rearrangements 
or FLT3-ITD mutations had elevated HoxA9 and Bcl-2 
expression levels (FDR p< 0.05). Thus, even in a diverse 
Figure 6: Association between HoxA9 and Bcl-2 expression in human leukemic lines. (A) Expression of HoxA9 and Bcl-2 in 
human leukemic lines. Total cell lysates were harvested and probed with antibodies against HoxA9, Bcl-2 and actin was used as a loading 
control. * Unknown band, which may be a HoxA9 splice variant. (B) Sensitivity of human leukemic lines expressing HoxA9 to Bcl-2 
inhibitor ABT-199. Human leukemic cells expressing higher levels of endogenous HoxA9 were treated or not with 1μM of ABT199 for 
48hs. Cell survival was determined by flow cytometric analysis of PI exclusion. Results show means ±SEM of 3 independent experiments. 
(C) Expression of HoxA9 (2 probesets – 209905_at and 214651_s_at) and Bcl-2 (one probeset – 203685_at) from 285 AML samples 
grouped into each of 16 clusters characterized by gene expression profiles previously defined by Valk et al [29] (GSE1159). Where a 
cluster is also associated with a particular genetic lesion, this is shown on the right of each cluster and where no such association exists 
this is shown as “none”. Bright bars indicate the clusters characterized by significant association between HoxA9 and Bcl-2 expression. 
Expression for each cluster is shown relative to the normal control group (NBM and CD34+, n=8). Significant genes were defined as BH-
adjusted p<0.05. (D) Expression of MLL-AF9, HoxA9 and Bcl-2 in MLL-AF9 immortalized cell lines. Hematopoietic progenitor cells 
were immortalized by infection with lentivirus encoding MLL-AF9 under the control of a tetracycline-repressible promoter. Cells were 
cultured in the absence (Day 0) or presence of 100ng/ml doxycycline for 3 and 5 days. Lysates were harvested and probed with antibodies 
against MLL, HoxA9, Bcl-2 and actin was used as a loading control.
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human population of cytogenetically complex disease, 
the association between elevated HoxA9 and Bcl-2 
expression could be observed. This was complemented 
by analysis of a second array dataset that compared 
silenced to control HoxA9 expression in AML cell lines 
with 11q23 rearrangements (GSE13714) (Supplemental 
Figure S4A). Bcl-2 expression was significantly reduced 
in cells expressing each of 2 independent HoxA9 short 
hairpin constructs, compared to control constructs (FDR 
p<0.05). To directly test whether MLL-rearrangements 
could regulate HoxA9 and Bcl-2 expression, we infected 
murine hematopoietic progenitor cells with lentivirus 
encoding MLL-AF9 under the control of a doxycycline-
repressible promoter [30]. In the presence of MLL-AF9, 
both HoxA9 and Bcl-2 expression were elevated. When 
MLL-AF9 expression was repressed, HoxA9 and Bcl-2 
expression declined (Figure 6D). These data emphasize the 
direct correlation between HoxA9 and Bcl-2 expression, 
both in established human AML cell lines and in patient 
samples. This appears to be strongest in AML with 11q23 
rearrangements and/or FLT3-ITD mutations. 
Figure 7: Loss of Bcl-2 expression delays AML models in vivo. (A-B) Survival of AML-burdened mice after transplantation with 
HoxA9/Meis1- (left panel) or MLL-AF9- (right panel) transformed cells of wild-type (filled lines) and Bcl-2-/- (dashed lines) genotypes. 
Number of mice used in each group indicated in brackets (wt/ Bcl-2-/-). GFP control mice (dotted lines) from the same experiment did not 
develop disease independent of the genotype, thus confirming the potential of engraftment of Bcl-2-/-. (***) P < 0.0005; (****) P <0.0001. 
All mice transplanted with Bcl-2-/- transformed AML cells presented a low white blood cell count compared to wild-type transplanted mice. 
Shown are the total numbers of white blood cells in peripheral blood ±SEM of mice bearing HoxA9/Meis1 (C) or MLL-AF9 (D) induced 
AML of the indicated genotype; (E and F) Representative data of the proportion of cells with morphologic features of blasts following May 
Grunwald Giemsa staining of blood smears preparation. Magnification 40x or inset 100x. Scale bar 100µm.
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Bcl-2 deletion delays AML progression.
To determine whether Bcl-2 expression plays a role 
in HoxA9-dependent leukemias in vivo, hematopoietic 
progenitor cells from C57BL6/Ly5.2 Bcl-2+/+ (wt) or Bcl-
2-/- embryos were transduced with retrovirus expressing 
HoxA9/Meis1, MLL-AF9 or GFP and then transplanted 
into irradiated C57BL6/Ly5.1 recipients. All mice that 
received Bcl-2+/+ cells transduced with HoxA9/Meis1 
or MLL-AF9 developed rapid and aggressive leukemia 
with an average latency of 40 days (Figure 7A and 
B). Transplantation of GFP infected cells resulted in 
engraftment and reconstitution of normal hematopoiesis. 
Transplantation of Bcl-2-/- cells significantly delayed the 
Figure 8: AML transplantation of Bcl-2-defcient cells induced destructive disease in spleen. (A) Histological comparison 
of bone marrow from GFP and mice burdened with HoxA9/Meis1-induced AML of wild-type and Bcl-2-/-. Magnification 20x, scale bar 
200µm.  The top panels show the presence of leukemic blasts in HoxA9/Meis1 symptomatic (anemia, splenomegaly, elevated leukocytes 
count) mice. The bottom panels are representative flow cytometry analysis of Mac-1 and Gr-1 expression in bone marrow cells. Data show 
a uniform Mac-1/Gr-1 positive population in cells from HoxA9/Meis1 AML independent of the genotype. (B) Histological examination of 
spleens from GFP control and mice burdened with HoxA9/Meis1 AML. Hematoxylin and eosin stained sections show presence of blasts 
in spleens of mice transplanted with wild-type and Bcl-2-/- HoxA9/Meis1, confirming AML development in both genotypes. Top panels 
of GFP and HoxA9/Meis1 magnification 10x, scale bar 500µm; lower panels, magnification 40x, scale bar 100µm. Despite the presence 
of blast cells and similar profile of splenomegaly (C), mice transplanted with Bcl-2-/- HoxA9/Meis1 cells presented fewer splenic follicles 
(B and D). (D) Data represent splenic follicles score values from the indicated genotypes. Splenic follicles were blinded score from 1 to 
5 with the maximum score being applied to spleens presenting splenic follicles as high as GFP control mice. Analysis was performed in 3 
sections from each mouse. 



























































development of leukemias for up to 30 days (Figure 7A 
and B). Interestingly, there was a significant reduction 
in white blood cell count of Bcl-2-/- reconstituted mice 
compared to wild-type, even as mice became sick (Figure 
7C and D). The majority of animals transplanted with 
Bcl-2-/- cells presented low blast cell counts in peripheral 
blood (Figure 7E and F). These results show that Bcl-2 
expression contributes to the leukocytosis in these models 
of AML and is an important variable determining the 
disease severity.
Bcl-2-/- transplanted mice developed a disease 
characterized by diminished leukocytosis, but as in 
wild type mice, developed splenomegaly and bone 
marrow infiltration. We analyzed H&E stained sections 
of bone marrow and spleen, and used flow cytometry 
and immunostaining to compare expression of surface 
antigens in bone marrow derived AML cells. Bone 
marrow from wild-type and Bcl-2-/- HoxA9/Meis1 mice 
displayed similar phenotypic characteristics, with the 
marrow consisting almost entirely of blasts with uniform 
expression of Mac-1 (CD11b) and Gr-1 (Figure 8A), 
typical signs of AML. The spleens of wild-type and Bcl-
2-/- engrafted mice were enlarged (Figure 8B and C). 
However, we observed a clear morphological distinction 
between the splenic architecture of wild-type and Bcl-2-
/- AML. Wild-type AML spleens had similar numbers of 
splenic follicles as GFP mice. In contrast, Bcl-2-/- AMLs 
had significantly fewer splenic follicles, indicative of a 
more destructive local disease (Figure 8A and D). Thus, 
the AML caused by transplantation of Bcl-2-deficient cells 
was characterized by delayed onset, significantly lower 
peripheral white cell counts and more destructive disease 
in organs such as the spleen. This suggests that Bcl-2 is 
required for survival of leukemic cells in peripheral blood, 
but not in the microenvironment of the bone marrow or 
spleen.
DISCUSSION
HoxA9 overexpression is a feature of leukemia 
with MLL rearrangements, trisomy 8 [7] and the t(7:11)
(p15:p15) translocation that fuses the homeodomain 
of HoxA9 to Nup98 [8]. The leukemogenic effects of 
HoxA9 overexpression include promoting leukemic cell 
self-renewal and inhibiting differentiation [9-12]. Here we 
show that HoxA9 overexpression maintains expression of 
Bcl-2, which, in vitro, is important for HoxA9-dependent 
immortalization, and in vivo, permits the full manifestation 
of AML, in particular the survival of AML cells in the 
peripheral circulation.
This specific role for Bcl-2 in myeloid cell 
immortalization and AML progression adds to the work 
that established Mcl-1 as the critical anti-apoptotic 
Bcl-2-like protein in AML [21]. Deletion of Mcl-
1 prevents engraftment in several AML models and 
prevents development of AML in secondary recipients. 
However, in this study, conditional deletion of Bcl-2 
was not tested. Using similar models to Glaser et al, we 
find that Bcl-2 expression has a role in the progression 
of AML, but not in the development of the disease. 
Accordingly, higher Bcl-2 expression is associated with 
increase severity, higher peripheral white cells counts 
and shorter survival of HoxA9-driven AML. In human 
AML, there is an association between elevated Bcl-2 
expression and increased white cell counts [31], however 
it is not yet known to what extent this is driven by MLL-
rearrangements or HoxA9. 
Our results indicate that AML, characterized either 
by elevated HoxA9 expression, MLL- rearrangements 
or elevated Bcl-2 expression, may be treated with drugs 
such as ABT-737 or the more specific Bcl-2 antagonist, 
ABT-199, that target anti-apoptotic Bcl-2 family members. 
Human AML cells lines with 11q23 rearrangements (in 
addition to many other genetic alterations) were, to 
greater or lesser degrees, killed by ABT-737, as has 
been previously characterized [32]. However, our in vivo 
models provide an important consideration in the use 
of these agents in AML. Bcl-2 deletion delayed disease 
progression, probably because the peripheral blast count 
was reduced. However, this did not prevent the progression 
of AML within organ niches such as the spleen and bone 
marrow. Thus, whilst it is the case that Bcl-2 family 
proteins have a significant influence on the response of 
AML to chemotherapy, at least in an ex-vivo environment 
[32], one might anticipate that targeting Bcl-2 specifically 
would be useful primarily to reduce peripheral white blood 
cell counts in patients with significant leukocytosis and 
consequently delay the progression and severity of the 
disease. 
Despite the complexity of genetic lesions that will 
invariably be present in any population of patients with 
AML [33], we observed a correlation between elevated 
HoxA9 and Bcl-2 expression, particularly in association 
with 11q23 rearrangements or the expression of FLT3-
ITD. This subgroup of AML (and ALL) may be the 
patients most likely to gain some benefit from drugs like 
ABT-263 and ABT-199, which may reduce leukocytosis 
and delay disease progression. However, it is clear from 
our results and Glaser et al [21] that Mcl-1 is the principal 
Bcl-2 family member to target for inhibition to achieve 
complete clearance of AML.
The diminished numbers of peripheral Bcl-2-/- blasts 
compared to those resident in the spleen and bone marrow 
may result from cell autonomous differences between 
these cell populations.  Mcl-1 is absolutely required 
for the survival of the population of leukemic cells that 
permit serial transplantation of AML [21], the so-called 
leukemic stem cells. The peripheral AML blast population 
may contain significantly fewer such cells, but instead is 
enriched for cells with a specific requirement for Bcl-2 
to maintain survival. Alternatively, host dependent factors 
may be more important. The bone marrow and splenic 
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niche may provide abundant survival signals, including 
cytokines such as GM-CSF and IL-3 that maintain 
expression of Mcl-1 [34,35]. The absence of these signals 
in peripheral blood would result in a decline in Mcl-1 
levels and perhaps drive selection in favor of cells that 
maintain expression of other Bcl-2 proteins, whose levels 
are less dependent on external survival signals.
The association between HoxA9 and Bcl-2 
expression has been previously observed. HoxA9-
/- mice have reduced numbers of bone marrow myeloid 
and lymphoid progenitor cells [2] that may result from 
increased apoptosis of lineage-committed progenitor 
cells as well as defects in maturation. This is supported 
by the findings of increased apoptosis and decreased Bcl-
2 expression in the fetal thymus of HoxA9-/- mice [3]. 
Definitive evidence of direct regulation of Bcl-2 by HoxA9 
would require to localization of transcriptional complexes 
that include HoxA9 in conserved regulatory regions 
of Bcl-2.  However many other transcription factors, 
including c-Myc and Myb are also known to promote Bcl-
2 expression [36,37], and are also upregulated in HoxA9-
immortalised cells [17]. Thus HoxA9 may promote Bcl-2 
expression indirectly via these transcriptional regulators. 
Our results and others [11] show that HoxA9-Pbc 
interactions are required for HoxA9 function. Nup98-
HoxA9, on the other hand, no longer requires Bcl-2 for 
efficient immortalization of hematopoietic progenitor 
cells. Nup98-HoxA9 also does not require an intact Pbc-
interaction motif to promote immortalization or leukemia 
[38]. It will be interesting and informative to compare the 
genes directly regulated by HoxA9 and Nup98-HoxA9. 
Our results would predict that Bcl-2 would be among the 
differently regulated genes. 
In conclusion, we have identified Bcl-2 as a key 
protein mediating HoxA9-dependent immortalization. 
This adds Bcl-2-regulated apoptosis to the pathways 
that contribute to the oncogenic effects of HoxA9 
overexpression. Deciphering the molecular links between 
HoxA9 and the regulation of Bcl-2 family members will 
greatly expand the potential therapeutic strategies that may 
be used in malignancies in which HoxA9 overexpression 
plays a key role. 
MATERIAL AND METHODS
Mice and cell lines 
Mice (Bcl-2-/-, Bax-/-;Bak-/-, Mcl-1fl/fl, Bcl-xfl/fl, Bcl-2fl/
fl and Rosa26-Cre ERT2) from which IL-3- or GM-CSF-
dependent cell lines were derived, have been previously 
described [19-23,39,40]. Cells constitutively expressing 
IL-3 were generated by co-culture of HoxA9 FDM 
cells with fibroblasts (ψ2 cells) expressing IL-3 from 
a retrovirus (kind gift from Suzanne Cory). Cells were 
tested for endogenous IL-3 expression by determining 
their survival in liquid culture and soft agar in the absence 
of exogenous IL-3. All FDM lines were routinely cultured 
at 37°C in a 10% CO2 humidified atmosphere in DMEM 
low glucose media (Invitrogen) supplemented with 10% 
fetal calf serum, 50nM 4-OHT or 1ug/ml Doxycycline 
(Sigma) and 0.5ng/ml IL-3 and/or 2.5ng/ml GM-CSF 
(Peprotech). 293T cells and fibroblasts (Ψ2) cells were 
cultured in DMEM/ 10% FCS.
Cloning and lentiviral production
M.musculus Flag-HoxA9 was cloned into the 
MSCV-GFP retroviral vector and lentiviral inducible 
vectors pF 5xUAS SV40 puro GEV16 or pFTREtight 
MCS rtTAadvanced GFP  (doxycycline inducible). The 
hexapeptide-mutant Flag-HoxA9 was cloned into the 
lentiviral inducible vector pF 5xUAS SV40 puro GEV16. 
MSCV-Nup98-HoxA9 retroviral vector was previously 
described [38] as was HoxB8 lentiviral inducible vector 
[41]. Retrovirus and lentivirus production are detailed in 
supplemental material and methods.
Generation of FDM lines
IL-3- or GM-CSF-dependent myeloid cell lines 
overexpressing Flag-HoxA9, HoxB8 or Nup98-HoxA9 
were generated by retroviral or lentiviral transduction of 
hematopoietic progenitors from E14.5 fetal livers or bone 
marrow stem cells with the different constructs using a 
Retronectin-based protocol. MLL-AF9 tetracycline-
repressible cells were generated by retroviral transduction 
of myeloid progenitor cells from E14.5 fetal livers with 
pMSCV-IRES-AtTA and pSIN-TREtight-Red2-ires-
MLL-AF9 (a kind gift from Luke Dow and Scott Lowe). 
Three weeks after infection dsRed cells were sorted in 
culture in IMDM media containing 10%FCS and 5ng/ml 
IL-3. Infection and selection of cell lines are detailed in 
supplemental material and methods. 
Generation and culture of leukemic cells
All in vivo experiments were conducted in 
accordance with the guidelines of The Walter and Eliza 
Hall Institute Animal Ethics Committee. HoxA9/Meis1 
retroviral construct and MLL-AF9 retroviral construct 
were previously described [42,43]. Viral supernatants were 
produced in 293T cells by co-transfection of expression 
constructs and packaging plasmids. Fetal liver cells 
(E14.5) from C57BL/6 Ly5.2 mice were infected with viral 
supernatant using the retronectin protocol. Transduced 
cells were cultured in alpha-MEM medium (Invitrogen) 
supplemented with 10% FCS, 2mM L-glutamine, 100ng/
mL murine stem-cell-factor (Peprotech), 10ng/mL IL-
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6, 50ng/ml TPO and 10ng/ml Flt3 (WEHI). After two 
rounds of infection, cells were injected into sub-lethally 
g-irradiated (7.5 Gy) C57BL/6 Ly5.1 mice. Mice were 
collected when disease was evident. Parameters used to 
determine leukemia were weight-loss, enlarge spleen, 
anemia, lethargy and hunched posture. Leukemic cells 
were obtained from bone marrow of sick mice. Cells were 
cultured at 37°C in a 10% CO2 humidified atmosphere in 
IMDM media supplemented with 10% fetal calf serum and 
5ng/ml IL-3.  
Cell cycle, proliferation and apoptosis analysis 
Cell viability was determined by flow cytometry 
analysis of Annexin V-FITC/PI stained cells, as previously 
described [44]. Cell cycle analysis of total DNA content 
was performed as described [45] and analyzed using the 
ModFit software. Cell proliferation was determined by 
flow cytometric cell counts or trypan exclusion. Detailed 
methodology is described in supplemental material.
Western Blot and reagents
Cells were lysed in sodium dodecyl sulfate (SDS) 
buffer (50mM Tris-HCL, pH 6.8, 2% SDS, 10% glycerol 
and 2,5% β-mercaptoethanol) and boiled for 10 min. 
The antibodies used were; Anti-mouse Bcl-2 mAb (BD 
Biosciences), anti-Actin mAb and pAb anti-Bax and 
anti-Bak (Sigma), anti-Bad pAb (Cell Signaling), anti-
Bim pAb (Stressgen), anti-Puma pAb (ProSci), anti-
HoxA9 pAb and anti-MLL clone N4.4 mAb (Millipore), 
anti-Mcl-1 pAb (Rockland) and anti-Bcl-xL pAb (R&D 
Systems). pAb anti-Bid, anti-Bmf and anti-A1 pAb were 
a kind gift from Andreas Strasser, Lorraine O’Reilly and 
Marco Herold respectively. ABT-737 and ABT-199 was a 
kind gift from David Huang supplied by AbbVie [46,47].
Clonogenic assays
Clonogenic assays were performed as previously 
described [48]. 
Detailed methodology is described in supplemental 
Material and Methods.
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